Drugs / DNase I
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07635433 | Jul 2026 → Jun 2027 expected | chronic rhinosinusitis | The First Affiliated Hospital of Xinxiang Medical College | Not yet recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT05453695 | Jan 2023 → May 2026 overdue | infectious disease with sepsis | McMaster University | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04541979 Comparator | Jun 2020 → Jan 2022 | COVID-19 | Region Skane | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DNase I | “aerosolized DNase I to remove NETs and decrease respiratory distress” NCT04541979 ↗ |
| Known as | PRX-119 | “This study investigates the efficacy of i.v. administration of PRX-119, a PEGylated recombinant human DNase I with an extended half-life of ~12 h.” PMID 40705350 ↗ Jul 2025 |
| Modality | Protein / enzyme biologic | “a PEGylated recombinant human DNase I with an extended half-life of ~12 h” PMID 40705350 ↗ Jul 2025 |
| Route | Inhaled | “aerosolized DNase I” NCT04541979 ↗ |